Poll
Are CRISPR startups still worth investing in after the patent shakeup?
With the CRISPR patent landscape shifting in 2025–2026, investors are questioning whether the technology's commercial promise still justifies the legal and regulatory risks. Cast your vote on whether CRISPR startups remain a smart bet.
Options
Live results
Vote first to see results.
Emoji reactions
No reaction selected.
Comments
Please sign in to comment.
Share / embed
Quick info
- How do I vote in the "Are CRISPR startups still worth investing in after the patent shakeup?" poll?
- Select one option on the page to cast your vote; results update with community votes in real time.
- Can I view results without voting?
- Yes. Use the "I don't know / Show results" option, or access the results summary after voting.
Similar polls
Up to 10 suggestions from the same category and shared tags, sorted by vote count; this poll is excluded.
From the same category
Basic Sciences and BiotechnologyThe same site category as this poll.
- Is learning basic biology still useful now that AI can answer everything?
- Has single-cell sequencing genuinely changed how you think about gene expression?
- Are sustainable biotech startups worth the hype over big pharma?
- Would you ever skip a pricey biotech course and just learn the basic science yourself?
- Would you switch from E. coli to yeast expression systems for higher protein yield?
- Is animal testing in biotech research a necessary evil or an outdated practice that we’ve already outgrown?
- With CRISPR costs dropping, are you still using older gene-editing methods?
- Can gene editing really fix our food supply as climate change worsens?
- Is CRISPR-based editing too reckless for human trials, or are ethical fears holding back a revolution?
- Is synthetic biology overhyped or the next big thing in basic sciences?
TrendVersus.com · live data